Growth Hormone System – Physiology, Signaling, Disorders, and Therapeutics
Growth Hormone System – Physiology, Regulation, Pathology, and Therapeutics
Overview
The anterior pituitary is regulated via the hypothalamic-pituitary (HP) axis, with several cell types producing stimulating hormones that act on peripheral targets.
This notes focus on the growth hormone (GH) axis, including its hypothalamic release, pituitary secretion, the downstream actions of GH, and the clinical implications.
Hypothalamic control and release of GH
Growth hormone releasing hormone (GHRH) is a bulky peptide synthesized in the arcuate nucleus of the hypothalamus.
GHRH travels down the hypophysioportal (hypophyseal portal) system to the anterior pituitary, binding to GHRH receptors on somatotropes to stimulate GH release.
GHRH action is pulsatile, reflecting hypothalamic firing patterns; GH release from the pituitary is also pulsatile and variable throughout the day, with peaks generally during the early sleep period.
GHRH is primarily responsible for GH release but other hypothalamic factors can modulate GH and prolactin release; thyroid-releasing hormone (TRH) may have minor cross-talk with prolactin release (not clinically central in GH regulation).
GHRH pharmacology/tools:
Somatorelin (a full-length form of GHRH) and sermorelin (a truncated analog) are used clinically, primarily for diagnostic purposes to assess GH reserve.
GH structure and isoforms; clinical relevance of isoforms
GH is a large peptide with two splice variants:
and (two active forms).
Endogenous GH is typically a mixture of these isoforms in a characteristic ratio; exogenous GH (e.g., for doping) is heavily skewed toward the 22 kDa form.
The relative abundance of isoforms can be used diagnostically to detect exogenous GH administration; endogenous GH shows a roughly ~9:1 ratio (22 kDa : 20 kDa) whereas exogenous GH can produce ratios like or higher.
Functionally, both isoforms are active and do not differ significantly in their physiological effects.
GH synthesis, release, and primary downstream mediator
GH released from the anterior pituitary acts on many tissues including fat, bone, liver, and muscle.
The principal peripheral mediator of GH action is insulin-like growth factor 1 (IGF-1), produced mainly by the liver, but also by other tissues in smaller amounts.
GH stimulation leads to IGF-1 production; IGF-1 then mediates many of the growth-promoting effects.
Receptors and signaling:
GH receptor (GH-R) activation engages a tyrosine kinase pathway, typically described as JAK-STAT signaling in classic pharmacology texts.
The signal from GH via GH-R promotes transcriptional responses, notably IGF-1 production.
IGF-1 signaling occurs primarily through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase; its main intracellular substrate is IRS-1 (insulin receptor substrate-1).
IGF-1 signaling and downstream pathways
IGF-1 binding to IGF-1R activates downstream cascades, chiefly:
The AKT pathway (cell survival, anti-apoptosis, metabolism, and growth-related processes).
The ERK/MEK pathway (cell proliferation and division).
The signaling cascades support growth by both reducing cell death and promoting cell division.
IGF-1 signaling and insulin signaling have substantial overlap due to cross-talk with insulin receptors, contributing to metabolic integration.
IGF-1 exerts negative feedback on GH axis:
High IGF-1 levels inhibit GH release and GHRH signaling.
IGF-1 also contributes to the negative feedback loop that tempers GH production.
Additional negative regulators of GH axis
Somatostatin (also known as SRIF) inhibits GH release at the hypothalamic and pituitary levels.
Dopamine D2 receptor activity can also suppress GH (and prolactin) release in certain contexts.
Ghrelin, an orexigenic peptide produced in the stomach, is involved in feeding and energy balance and can influence GH release by interacting with the hypothalamic network (notably, ghrelin is associated with stimulating appetite; its relationship to somatostatin and GH is context-dependent).
GH release dynamics and physiological context
GH and IGF-1 are part of a coordinated growth program that aligns with energy availability and growth demands.
There is overlap with metabolic signals: GH promotes a metabolic switch from predominantly glucose utilization to fat utilization and protein synthesis under certain conditions; IGF-1 supports tissue growth and development.
Growth hormone and IGF-1 interplay with stress and exercise; cortisol and HPA-axis activity can modulate this axis acutely.
The rise of GH with age is generally from youth through puberty and then declines with aging post-puberty.
Clinical and diagnostic use of GH-related agents
Growth Hormone-releasing hormone (GHRH) analogs and related peptides are used for diagnostic testing of GH reserve (e.g., somatorelin, sermorelin).
Pièce de résistance of diagnostic context: evaluating endogenous GH axis function rather than treating disease per se.
Growth hormone disorders (pre- vs post-puberty) and clinical consequences
Gigantism (pre-pubertal GH excess)
Excess GH signaling before puberty leads to excessive overall growth with high IGF-1 and disproportionately large stature.
Individuals typically achieve very tall stature (often well over 7 feet) and may approach 8 feet in extreme cases.
Lifespan can be reduced due to cardiovascular complications; some cases involve additional health challenges related to very large body size.
Often associated with pituitary adenomas producing excess GH.
Acromegaly (post-pubertal GH excess)
GH excess after puberty when epiphyseal plates have fused.
Features include enlarged hands/feet, prognathism (protruding jaw), brow prominence, deepening of voice, and soft tissue swelling.
Common complaints include chronic pain, headaches, joint pain, and glucose intolerance; cardiovascular disease risk increases.
Dwarfism (GH deficiency pre-puberty)
Insufficient GH signaling leads to delayed growth and short stature; proportional or disproportionate short stature depending on etiology.
Affected individuals often have reduced exercise tolerance and muscle development, due to GH’s role in metabolism and growth.
The spectrum includes other etiologies (e.g., receptor mutations causing IGF-1 insensitivity) that affect growth despite GH signaling.
Therapeutics for GH excess and deficiency
Somatostatin analogs (e.g., octreotide, lanreotide)
Mechanism: long-acting analogs that inhibit GH release from the pituitary and reduce IGF-1 production.
Dosing: often given via monthly injections using slow-release formulations.
Effects: decrease GH and IGF-1 levels; may cause gastrointestinal side effects (gas, bloating, constipation) due to GI motility effects.
Broad action: because somatostatin receptors are widespread, these agents can suppress multiple anterior pituitary hormones and impact energy metabolism, immune function, and more; monitoring of other hormones is required.
Dopamine agonists (D2 receptor agonists)
Used to reduce GH and IGF-1 levels in many acromegaly patients; can sometimes be combined with somatostatin analogs for additive effects.
Also used to lower prolactin levels in other conditions.
GH receptor antagonists (GH-R antagonists)
Pegvisomant (brand Somavert) is a modified GH analog that blocks GH receptor activation, reducing IGF-1 production while GH levels can remain elevated.
Useful in acromegaly to control IGF-1 without broadly suppressing upstream hypothalamic-pituitary signaling.
HGH (growth hormone) replacement therapy for deficiency
Recombinant human GH (somatropin) is used in children with GH deficiency to promote growth through puberty and catch-up growth.
In adults, GH is used in some contexts for cachexia and other conditions, but off-label use for anti-aging or athletic enhancement is controversial and potentially risky.
Risks include potential promotion of tumorigenesis due to anti-apoptotic and proliferative signaling; long-term cancer risk remains a concern; use requires careful consideration and monitoring.
Long-acting GH formulations, such as Symetragon, allow weekly auto-injections for pediatric GH deficiency.
IGF-1 therapy (mechasermin analogs)
Increlex (mecasermin) is recombinant IGF-1 used for GH-insensitive or GH-deficient patients who do not respond adequately to GH therapy.
IGF-1 can be used directly when IGF-1-mediated growth is impaired despite GH signals.
Practical notes on GH biology and treatment considerations
GH action is highly integrated with energy status, insulin signaling, and other hormones; changes can impact glucose homeostasis and fat/protein metabolism.
When using somatostatin analogs or dopamine agonists, clinicians monitor for side effects and ensure that suppression of GH does not unfortunately compromise other pituitary functions.
When using pegvisomant, monitoring relies on IGF-1 levels rather than GH levels, because GH may remain elevated while IGF-1 is controlled.
The choice of therapy depends on the underlying cause (tumor, receptor insensitivity, deficiency) and patient-specific factors (age, comorbidities, risk of cancer, desired outcomes).
Quick reference pointers (key concepts and numbers)
GH release mechanism: GHRH → GH release from somatotropes; pulsatile pattern; peak GH with early sleep.
IGF-1: downstream mediator produced mainly by liver; promotes growth via AKT and ERK/MEK pathways; feeds back to suppress GH release.
Signaling overview: GH-R (via JAK-STAT) → IGF-1 production; IGF-1R → IRS-1 → PI3K/AKT (cell survival) and ERK/MEK (cell proliferation).
GH isoforms: and ; endogenous ratio approx. ; exogenous GH ratio often .
Connections to broader physiology and therapeutics
GH/IGF-1 axis intersects with nutrition, exercise physiology, and aging research due to its role in body composition, metabolism, and tissue regeneration.
Clinically, manipulation of this axis is used to treat pediatric and adult deficiencies or pathologic excess (acromegaly, gigantism), with careful balancing of benefits and oncogenic risk.
Ethical and practical considerations for GH therapy include off-label use and potential long-term risks, especially in older adults seeking anti-aging benefits.
Summary takeaways
GH is released from the anterior pituitary in response to hypothalamic GHRH; its downstream mediator IGF-1 drives growth and metabolism through IGF-1R signaling, with crucial feedback loops from IGF-1 and somatostatin.
Disorders arise depending on the timing of GH excess or deficiency (pre- vs post-puberty) and can present as gigantism, acromegaly, or dwarfism.
A range of therapeutics targets different nodes of the axis: somatostatin analogs, dopamine agonists, GH receptor antagonists, GH itself, and IGF-1, each with distinct benefits, risks, and monitoring needs.
Note: Some statements in the source material reflect clinical practice and terminology that may be presented with slight colloquial wording (e.g., ghrelin’s role in satiety versus appetite stimulation) and are included here to preserve the original instructional emphasis. In practice, ghrelin is typically described as an appetite-stimulating hormone that can influence GH release indirectly through hypothalamic pathways.
Growth Hormone (GH) System – Core Concepts for Study
The GH axis is regulated by the hypothalamic-pituitary (HP) axis.
Hypothalamic Control and GH Release
Growth Hormone Releasing Hormone (GHRH):
Synthesized in the arcuate nucleus of the hypothalamus.
Travels via the hypophysioportal system to the anterior pituitary.
Binds to GHRH receptors on somatotropes to stimulate GH release.
Release is pulsatile, with peaks during the early sleep period.
GHRH Pharmacology (Diagnostic Use):
Somatorelin and sermorelin are GHRH analogs.
Used diagnostically to assess GH reserve.
GH Structure and Isoforms
GH is a large peptide with two active splice variants:
and .
Clinical Relevance (Doping Detection):
Endogenous GH ratio: approximately ().
Exogenous GH ratio: often or higher (skewed towards ).
Both isoforms are functionally active.
GH Synthesis, Release, and Downstream Mediator
GH released from the anterior pituitary acts on fat, bone, liver, and muscle.
Primary Peripheral Mediator: Insulin-like Growth Factor 1 (IGF-1).
Produced mainly by the liver (also other tissues).
Mediates many growth-promoting effects of GH.
Receptors and Signaling
GH Receptor (GH-R) Activation:
Engages a tyrosine kinase pathway, typically JAK-STAT signaling.
Promotes transcriptional responses, notably IGF-1 production.
IGF-1 Receptor (IGF-1R) Signaling:
IGF-1R is a receptor tyrosine kinase.
Main intracellular substrate: IRS-1 (insulin receptor substrate-1).
Activates downstream cascades:
AKT pathway: Cell survival, anti-apoptosis, metabolism, growth.
ERK/MEK pathway: Cell proliferation and division.
Significant overlap with insulin signaling.
Regulation and Negative Feedback
IGF-1 Negative Feedback:
High IGF-1 levels inhibit GH release and GHRH signaling.
Additional Negative Regulators:
Somatostatin (SRIF): Inhibits GH release at hypothalamic & pituitary levels.
Dopamine D2 receptor activity: Can suppress GH (and prolactin).
Ghrelin: Can influence GH release by interacting with the hypothalamic network.
GH Release Dynamics and Physiological Context
GH and IGF-1 align with energy availability and growth demands.
GH promotes metabolic switch from glucose to fat utilization and protein synthesis.
GH levels rise from youth through puberty, declining with aging post-puberty.
Growth Hormone Disorders and Clinical Consequences
Gigantism (Pre-pubertal GH Excess):
Excess GH before puberty (epiphyseal plates open).
Leads to excessive overall growth (very tall stature, often > feet).
Reduced lifespan due to cardiovascular complications.
Often associated with pituitary adenomas.
Acromegaly (Post-pubertal GH Excess):
GH excess after puberty (epiphyseal plates fused).
Features:
Enlarged hands/feet.
Prognathism (protruding jaw), brow prominence.
Deepening voice, soft tissue swelling.
Common complaints: Chronic pain, headaches, joint pain, glucose intolerance.
Increased cardiovascular disease risk.
Dwarfism (GH Deficiency Pre-puberty):
Insufficient GH signaling.
Leads to delayed growth and short stature.
Reduced exercise tolerance and muscle development.
Therapeutics for GH Excess and Deficiency
Somatostatin Analogs (e.g., Octreotide, Lanreotide):
Mechanism: Long-acting analogs that inhibit GH release from the pituitary and reduce IGF-1 production.
Dosing: Often monthly injections.
Effects: Decrease GH and IGF-1; potential GI side effects.
Broad action: Can suppress multiple anterior pituitary hormones.
Dopamine Agonists (D2 receptor agonists):
Used to reduce GH and IGF-1 in some acromegaly patients (can combine with somatostatin analogs).
Also used for prolactin reduction.
GH Receptor Antagonists (e.g., Pegvisomant):
Mechanism: Modified GH analog that blocks GH receptor activation, directly reducing IGF-1 production.
Key point: GH levels can remain elevated while IGF-1 is controlled.
Useful in acromegaly.
HGH (Growth Hormone) Replacement Therapy (Somatropin):
Used in children with GH deficiency to promote growth.
Adult uses (cachexia) are limited; off-label use for anti-aging/athletic enhancement is controversial and risky.
Risks: Potential tumorigenesis, anti-apoptotic, and proliferative signaling.
IGF-1 Therapy (Mecasermin analogs):
Recombinant IGF-1 (Increlex).
Used for GH-insensitive or GH-deficient patients who do not respond to GH therapy.
Directly provides IGF-1 when IGF-1-mediated growth is impaired.
Practical Notes on GH Treatment
GH action is integrated with energy status, insulin signaling, and other hormones.
Monitoring:
For somatostatin analogs/dopamine agonists: Monitor side effects and other pituitary hormones.
For pegvisomant: Monitor IGF-1 levels (GH may remain high).
Therapy choice depends on underlying cause (tumor, receptor insensitivity, deficiency) and patient factors.